Introduction {#s1}
============

Ca^2+^ and cAMP are ubiquitous intracellular messengers that regulate most cellular behaviors. The versatility of these messengers depends on both the spatiotemporal organization of the changes in their concentration within cells ([@B6]) and on interactions between them \[see references in [@B41]\]. These interactions are important in many smooth muscles, where increases in intracellular free Ca^2+^ concentration (\[Ca^2+^\]~i~) stimulate contraction, but receptors that stimulate formation of cAMP usually cause relaxation. The clinical importance is clear from the widespread use of *β*-agonists to provide symptomatic relief from asthma ([@B24]). In vascular smooth muscle (VSM), too, cAMP attenuates the contractile responses mediated by many receptors that evoke Ca^2+^ signals ([@B23]). This inhibition is assumed to be mediated by cAMP-dependent protein kinase (PKA) ([@B25]), but there are also PKA-independent effects of cAMP ([@B36]). At least some of these effects may be through exchange proteins activated by cAMP (EPACs), probably EPAC 1, which is abundant in blood vessels particularly within endothelial cells ([@B31]).

Histamine and prostaglandin E~2~ (PGE~2~) are two important inflammatory mediators. Their effects on VSM, which include regulation of proliferation ([@B44]) and vascular tone ([@B40]; [@B14]), are mediated by direct interactions with VSM and indirectly through release of autocrine signals from other cells ([@B26]). Histamine, PGE~2~ and their receptors are also implicated in vascular pathology, including inflammation ([@B26]), atherosclerosis ([@B11]), and restenosis ([@B33]).

We demonstrated previously that histamine, through H~1~ receptors, stimulates an increase in \[Ca^2+^\]~i~ in human aortic smooth muscle cells (ASMC). The initial response is mediated by Ca^2+^ release through inositol 1,4,5-trisphosphate receptors (IP~3~R) and it is followed by Ca^2+^ entry across the plasma membrane ([@B28]). PGE~2~, acting largely through EP~2~ receptors, both stimulates the activity of adenylyl cyclase (AC) and substantially attenuates the Ca^2+^ signals evoked by histamine. Here, we show that inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ is mediated by cAMP delivered within "hyperactive signaling junctions." The response does not require EPACs, but it is attenuated by inhibition of PKA. The effect of PGE~2~ on histamine-evoked Ca^2+^ signals does not result from a decrease in IP~3~R sensitivity or from increased Ca^2+^ extrusion from the cytosol, nor does PGE~2~ affect the Ca^2+^ signals evoked by stimulation of either endogenous type 1 protease-activated receptor (PAR1) or heterologously expressed muscarinic M3 acetylcholine receptors. We suggest that PKA uncouples H~1~ histamine receptors from the guanine nucleotide-binding protein, G~q/11~, and activation of phospholipase C (PLC). Our results establish that digital signaling from PGE~2~ receptors, through cAMP and PKA, inhibits histamine-evoked Ca^2+^ signals.

Materials and Methods {#s2}
=====================

 {#s3}

### Materials. {#s4}

H89, NKH 477, 8-Br-cAMP, and 8-Br-cGMP were from R&D Systems (Abingdon, Oxford, UK). *S*p-cAMPS, 6-Bnz-cAMP, 8-pCPT-2′-O-Me-cAMP, *R*p-cAMPS, *R*p-8-CPT-cAMPS, ESI-09, and HJC0197 were from Biolog (Bremen, Germany). Ionomycin, SQ 22536, DDA and myristoylated-PKA inhibitor peptide (PKI) were from Merck-Millipore (Watford, UK). A membrane-permeant peptide inhibitor of A kinase-anchoring proteins (AKAPs) \[stearated Ht31 AKAP inhibitor peptide (st-Ht31)\] and its proline-modified inactive form (st-Ht31P) were from Promega (Southampton, UK). Thapsigargin was from Alomone Laboratories (Jerusalem, Israel). PAR1 peptide, histamine dihydrochloride, forskolin, IBMX, and PGE~2~ were from Sigma-Aldrich (Welwyn Garden City, UK). Butaprost (free acid) and L902,688 were from Cayman Chemicals (Ann Arbor, MI). Membrane-permeant caged IP~3~ (ci-IP~3~PM) was from SiChem (Bremen, Germany). \[2,8-^3^H\] adenine ci-IP~3~PM, [d]{.smallcaps}-2,3-O-isopropylidene-6-O-(2-nitro-4,5-dimethoxy)benzyl-myo-inositol 1,4,5-trisphosphate-hexakis(propionoxymethyl) ester was from Perkin Elmer (Seer Green, Bucks, UK). Fluo-8 was from Stratech Scientific Ltd (Newmarket, Suffolk, UK). Other reagents were from Sigma-Aldrich, sources specified previously ([@B28]) or identified in this section.

### Culture of Human Aortic Smooth Muscle Cells. {#s5}

Human ASMC from the American Tissue Culture Collection (Manassas, VA) or Dr. Trevor Littlewood ([@B3]) were cultured as described ([@B28]). Ethical approval for the latter was obtained from Addenbrooke's NHS Trust. Cells were derived from four Caucasian patients (males aged 23, 52, and 54, and a female aged 58), who died of causes unrelated to cardiovascular pathologies. Cells were used between passages two and six.

### Measurements of \[Ca^2+^\]~i~. {#s6}

Histamine-evoked changes in \[Ca^2+^\]~i~ were recorded from cell populations using confluent cultures of ASMC grown in 96-well plates and loaded with Fluo-4 or Fluo-8. Experiments were performed in HEPES-buffered saline (HBS) at 20°C. HBS had the following composition (mM): NaCl 135, KCl 5.9, MgCl~2~ 1.2, CaCl~2~ 1.5, glucose 11.5, and HEPES 11.6 (pH 7.3). Fluorescence was recorded using a FlexStation 3 fluorescence plate-reader (MDS Analytical Technologies, Wokingham, UK) and calibrated to \[Ca^2+^\]~i~ as described ([@B28]).

For measurements of \[Ca^2+^\]~i~ in single cells, confluent cultures of ASMC grown on poly-[l]{.smallcaps}-lysine-coated coverslips (22-mm diameter) were loaded with Fura-2 in HBS containing Fura-2 AM (4 *μ*M), probenecid (2.5 mM), and pluronic F127 (0.02% v/v) for 1 hour at 20°C. Fluorescence (detected at \>510 nm with alternating excitation at 340 and 380 nm) was recorded using an Olympus IX71 inverted fluorescence microscope and Luca (electron-multiplying charge-coupled device) EMCCD Andor Technology, Belfast, UK camera. After correction for background fluorescence, determined by addition of ionomycin (1--5 *μ*M) in HBS containing MnCl~2~ (1 mM), fluorescence ratios (F~340~/F~380~) were calibrated to \[Ca^2+^\]~i~ ([@B42]).

### Measurements of Intracellular cAMP. {#s7}

Confluent cultures of ASMC grown in 24-well plates and labeled with ^3^H-adenine were incubated under conditions that replicated those used for measurements of \[Ca^2+^\]~i~. Reactions were terminated by aspiration of medium and addition of ice-cold trichloroacetic acid (5% v/v, 1 ml). After 30 minutes on ice, ^3^H-cAMP was separated from other ^3^H-labeled adenine nucleotides ([@B28]).

### Expression of PKI and M3 Muscarinic Receptors. {#s8}

Plasmids encoding PKI (pRSV-PKI-v2) and its inactive form (pRSV-mut PKI-v2) were from Addgene (cat. no. 45066 and cat. no. 45067; Cambridge, MA) ([@B8]); they were C-terminally tagged with mCherry. Plasmid encoding the human M3 muscarinic acetylcholine receptor was from the cDNA Resource Centre (cat. no. MAR0300000) ([@B9]). The three constructs were each recombined into BacMam pCMV-DEST. Bacmids were then prepared, and virus was produced from bacmid-infected Sf9 cells according to the manufacturer's instructions (Thermo Fisher Scientific, Runcorn, UK). ASMC were infected at a multiplicity of infection (MOI) of ∼50 and used after 96 hours.

### Flash Photolysis of Caged IP~3~. {#s9}

Confluent cultures of ASMC grown on poly-[l]{.smallcaps}-lysine-coated imaging dishes (35-mm diameter with a 7-mm glass insert; MatTek Corporation, Ashland, MA) were loaded (45 minutes, 20°C) with a membrane-permeant form of caged IP~3~ (ci-IP~3~PM, 1 *μ*M) in HBS with probenecid (2.5 mM) and pluronic F127 (0.02% v/v). Fluo-4 AM (4 *μ*M) was then added and after 45 minutes at 20°C, the medium was replaced with HBS containing only probenecid. After a further 45 minutes, this medium was replaced with HBS. Cells were illuminated with a 488-nm diode-based solid-state laser, and emitted fluorescence (500--550 nm) was captured with an EMCCD camera. Three UV flashes (each ∼1-millisecond duration; \<345 nm, 3000 *μ*F, 300 V, ∼170 J) from a JML-C2 Xe flash-lamp (Rapp OptoElectronic, Hamburg, Germany) allowed photolysis of caged IP~3~ (ci-IP~3~). Responses are reported as F/F~0~, where F~0~ and F are fluorescence intensities corrected for background recorded from the same region of interest immediately before (F~0~) and after stimulation (F).

### Measurements of IP~3~ and PLC Activity. {#s10}

ASMC in 12-well plates were cultured until confluent. The medium was then supplemented with [d]{.smallcaps}-*myo*-\[2-^3^H\]-inositol (10 *μ*Ci/ml) for 48 hours at 37°C. After washing, cells were incubated at 20°C in HBS with LiCl (10 mM) for 5 minutes before stimulation. Reactions were terminated by aspirating medium and adding cold HClO~4~ (1 ml, 0.6 M) containing phytic acid (0.2 mg/ml). After 30 minutes, the acid-extract was removed, the cells were scraped into 50 mM Tris at pH 7 (400 *μ*l), and the pooled extract and cells were centrifuged (10,000*g,* 2 minutes, 4°C). The supernatant was neutralized using K~2~CO~3~ (1 M) with EDTA (5 mM). ^3^H-inositol phosphates were separated using ion-exchange columns.

For assays of IP~3~ mass, ASMC in 75-cm^2^ flasks were stimulated, the medium was removed, and the incubations were terminated by scraping cells into ice-cold ethanol (1 ml). After 30 minutes, extracts were dried and suspended in 300 *μ*l of Tris-EDTA medium (TEM: 50 mM Tris, 1 mM EDTA, pH 8.3). Equilibrium-competition binding using ^3^H-IP~3~ (4.5 nM, 19.3 Ci/mmol), rat cerebellar membranes (10 *μ*g) and cell extract (20--100 *μ*l) in a final volume of 200 *μ*l of TEM was used to determine the IP~3~ content of the extracts ([@B32]).

### Immunoblotting. {#s11}

Confluent ASMC in 75-cm^2^ flasks or six-well plates were stimulated and then scraped into cold phosphate-buffered saline supplemented with Triton-X-100 (1% w/v), protease inhibitors (one mini-tablet per 10 ml; Roche Applied Science, Burgess Hill, UK), and phosphatase inhibitors (10 *μ*l/ml; Sigma-Aldrich). Scraped cells were disrupted by ∼30 passages through a 28-gauge needle and sonicated (3 × 10 seconds). Proteins were separated by SDS-PAGE (NuPAGE 4%--12% Bis-Tris gels; Invitrogen, Paisley, UK) and transferred to a polyvinylidene difluoride membrane (iBlot; Invitrogen). Membranes were washed (5 minutes) with Tris-buffered saline (TBS: 137 mM NaCl, 20 mM Tris, pH 7.6), blocked by incubation in TBS containing 0.1% Tween-20 (TBS-T) and 5% (w/v) nonfat milk powder (1 hour, 20°C), and then washed with TBS-T (3 × 5 minutes). Blots were incubated for 12 hours at 4°C with primary antibody (1:1000) in TBS-T with 5% (w/v) BSA. After washing (3 × 5 minutes), blots were incubated with horseradish peroxidase-conjugated donkey anti-rabbit secondary antibody (1:2000; Santa Cruz Biotechnology, Dallas, TX) for 1 hour in TBS-T with 5% (w/v) nonfat milk powder. After further washing (3 × 5 minutes), bands were detected using ECL Prime (GE Healthcare, Chalfont St Giles, UK) and quantified using GeneTools (Syngene, Cambridge, UK). The primary rabbit antibodies recognize PKA-phosphorylated sequences RXXS\*/T\* (AbP1, AbP2, cat. nos. 9621 and 9624; New England Biolabs, Hitchin, UK; \* denotes the phosphorylated residue) and vasodilator-stimulated phosphoprotein (VASP \[clone 43, BD Biosciences, San Jose, CA\]) phosphorylated at Ser-157 (New England Biolabs) or VASP clone 43 (BD Biosciences, San Jose, CA).

### Quantitative PCR Analysis. {#s12}

QPCR was performed as described ([@B41]) using primers specific for AC subtypes ([@B18]) and calibrated against expression of the house-keeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) ([@B28]). Human BioBank cDNA pooled from a variety of tissues (Primerdesign, Southampton, UK) was used as a positive control for AC subtypes not expressed in ASMC.

### Statistical Analysis. {#s13}

Concentration-effect relationships were individually fitted by nonlinear curve-fitting to Hill equations (GraphPad Prism, La Jolla, CA). The absolute sensitivities and amplitudes of the responses to histamine and PGE~2~ varied between patients and with cell passage. Results are, therefore, often presented as normalized values (e.g., as percentages of a maximal response) or as differences between paired comparisons (e.g., *Δ*pIC~50~). Two-tailed paired or unpaired Student's *t* test, or one-way analysis of variance followed by Bonferroni's test, were used as appropriate.

Results {#s14}
=======

 {#s15}

### Cyclic AMP Mediates Inhibition of Histamine-Evoked Ca^2+^ Signals by PGE~2~. {#s16}

[Figure 1A](#F1){ref-type="fig"} demonstrates that PGE~2~ inhibits the Ca^2+^ signals evoked by histamine in human ASMC. Most experiments were performed at 20°C to minimize loss of the cytosolic Ca^2+^ indicator. However, in parallel analyses we confirmed that a maximally effective concentration of PGE~2~ (10 *μ*M) caused indistinguishable inhibition of the Ca^2+^ signals evoked by histamine (100 *μ*M) whether the analyses were performed at 20°C (47% ± 12% inhibition, *n* = 4) or 37°C (45% ± 6%). In parallel measurements of the effects of PGE~2~ on intracellular cAMP and histamine-evoked Ca^2+^ signals, the cAMP response \[negative logarithm of the half-maximally effective concentration (pEC~50~) = 6.76 ± 0.09, *n* = 4) was ∼140-fold less sensitive to PGE~2~ than were the Ca^2+^ signals \[negative logarithm of the half-maximally inhibitory concentration (pIC~50~) = 8.90 ± 0.10, *n* = 6\] ([Fig. 1B](#F1){ref-type="fig"}). This relationship is consistent with PGE~2~ evoking formation of more cAMP than needed to maximally inhibit Ca^2+^ signals, and with cAMP lying upstream of the inhibition of Ca^2+^ signaling ([@B37]).

![Inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ is mediated by cAMP. (A) Ca^2+^ signals evoked by histamine (3 *μ*M, black bar) alone or with PGE~2~ (10 *μ*M, added 5 minutes before and then during stimulation with histamine). Results show means ± range from two wells on a single plate; they are typical of results from at least four independent experiments. (B) Effects of PGE~2~ on cAMP accumulation (measured after 5 minutes) and inhibition of the peak Ca^2+^ signals evoked by histamine (3 *μ*M). Results, as percentages of maximal inhibition (Ca^2+^) or stimulation (cAMP), are means ± S.E.M. from six and four experiments, respectively. This panel includes some data for cAMP measurements that were published previously ([@B28]). (C) Effect of NKH 477 (100 *μ*M) on the peak Ca^2+^ signal evoked by histamine. (D) Concentration-dependent effects of forskolin on the peak Ca^2+^ signals evoked by histamine (1 mM). (E) Effect of PGE~2~ (10 *μ*M), NKH 477 (100 *μ*M), or both on the peak Ca^2+^ signals evoked by histamine (as percentages of the maximal response). NKH 477, forskolin, or PGE~2~ were added 5 minutes before and then during stimulation with histamine. Results show means ± S.E.M. from four (C and D) or three (E) independent plates with one to three wells analyzed from each. Ct denotes control.](mol.117.109249f1){#F1}

Forskolin and its water-soluble analog, NKH 477, directly activate eight of the nine membrane-bound forms of AC (AC1--8) ([@B34]). Pretreatment of ASMC with NKH 477 caused a concentration-dependent reduction in both the peak amplitudes of the Ca^2+^ signals evoked by histamine and their sensitivity to histamine ([Fig. 1C](#F1){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). Similar results were obtained with forskolin ([Fig. 1D](#F1){ref-type="fig"}). Maximally effective concentrations of PGE~2~ and NKH 477 caused indistinguishable inhibition of histamine-evoked Ca^2+^ signals, and their combined maximal effects were not additive ([Fig. 1E](#F1){ref-type="fig"}). These results are consistent with reports showing that forskolin and NKH 477 attenuate the Ca^2+^ signals evoked by receptors, including H~1~ receptors that stimulate PLC in VSM ([@B43], and references therein) and other smooth muscles. There has, however, been no prior demonstration that activation of AC inhibits PLC-evoked Ca^2+^ signals in human ASMC.

###### 

Inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ and cAMP

Cells were incubated for the times shown with the indicated drugs before recording the peak increase in \[Ca^2+^\]~i~ evoked by histamine (3 *μ*M; 1 mM for forskolin and NKH 477). Results (means ± S.E.M. from *n* independent experiments) show the maximal inhibition of the histamine-evoked Ca^2+^ signals and the pIC~50~ for each drug.

                        pIC~50~       Maximal inhibition   *n*
  --------------------- ------------- -------------------- -----
                        /M            \%                   
  PGE~2~ (5 min)        9.01 ± 0.05   64 ± 4               9
  Butaprost (5 min)     7.28 ± 0.09   61 ± 1               6
  L902,688 (5 min)      9.35 ± 0.10   76 ± 4               5
  8-Br-cAMP (20 min)    2.98 ± 0.20   85 ± 3               3
  6-Bnz-cAMP (20 min)   3.73 ± 0.14   64 ± 5               5
  Forskolin (5 min)     6.24 ± 0.11   57 ± 6               4
  NKH 477 (5 min)       5.50 ± 0.18   53 ± 4               5

High concentrations of 8-Br-cAMP also inhibited histamine-evoked Ca^2+^ signals by reducing the maximal response and the sensitivity to histamine ([Fig. 2A](#F2){ref-type="fig"}). 8-Br-cAMP had no effect on the Ca^2+^ content of the intracellular stores ([Fig. 2B](#F2){ref-type="fig"}). The effects of 8-Br-cAMP were mimicked by *S*p-cAMPS, which activates PKA and EPACs, and by 6-Bnz-cAMP and 8-CPT-6-Phe-cAMP, which activate PKA but not EPACs ([Fig. 2C](#F2){ref-type="fig"}; [Supplemental Fig. S1](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.117.109249/-/DC1); and [Table 1](#T1){ref-type="table"}). A high concentration (10 mM) of 8-pCPT-2′-O-Me-cAMP, a membrane-permeant activator of EPACs; and *R*p-cAMPS and *R*p-8-CPT-cAMPS, antagonists of both PKA and EPACs, were ineffective ([Fig. 2D](#F2){ref-type="fig"}; [Supplemental Fig. S1](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.117.109249/-/DC1)).

![Cyclic AMP mediates inhibition of histamine-evoked Ca^2+^ signals by PGE~2~. (A) Effect of 8-Br-cAMP (added 20 minutes before histamine) on the peak Ca^2+^ signals evoked by the indicated concentrations of histamine. Results are means ± S.E.M. from at least three experiments with one to three wells in each. (B) 8-Br-cAMP (10 mM, 20 minutes) had no effect on the Ca^2+^ content of the intracellular stores as revealed by the increases in \[Ca^2+^\]~i~ evoked by addition of thapsigargin (1 *μ*M) or ionomycin (1 *μ*Μ) in Ca^2+^-free HBS. Results (percentages of responses without 8-Br-cAMP) are means ± S.E.M. from five experiments with three to four wells analyzed in each. (C) Effect of the indicated cyclic nucleotides (added 20 minutes before histamine) on the peak Ca^2+^ signals evoked by histamine (3 *μ*M). Results are means ± S.E.M. from three to five experiments with two to three wells in each. (D) Effect of NKH 477 (100 *μ*M, 5 minutes), forskolin (100 *μ*M, 5 minutes), 8-Br-cAMP (10 mM, 20 minutes), PGE~2~ (10 *μ*Μ, 5 minutes), 8-Br-cGMP (10 mM, 20 minutes), *R*p-cAMPS (10 mM, 20 minutes), or 8-pCPT-2*′*-O-Me-cAMP (10 mM, 20 minutes) alone or in combination on the peak Ca^2+^ signals evoked by histamine (1 mM). Results (as percentages of the response to histamine alone) are means ± S.E.M. from three experiments with two to three wells in each. Results for *R*p-cAMPS are from a single experiment with three replicates, limited by the availability of this expensive analog. (E) Effects of the EPAC antagonists, ESI-09 and HJC0197 (10 *μ*M, 20 minutes), on the Ca^2+^ signals evoked by histamine (3 *μ*M) added 5 minutes before and then during treatment with the indicated concentrations of PGE~2~. Results are expressed as percentages of the paired response to histamine alone (means ± S.E.M., *n* = 3--5; *n* = 2 for the antagonists with 1 and 3 nM PGE~2~, where error bars show ranges). (F) The results establish that cAMP mediates inhibition of histamine-evoked Ca^2+^ signals by PGE~2~.](mol.117.109249f2){#F2}

The negative result with 8-pCPT-2′-O-Me-cAMP is important because this analog is more membrane-permeable than 8-Br-cAMP, and it both binds with greater affinity than cAMP to EPACs and more effectively activates them ([@B10]). Furthermore, antagonists of EPACs 1 and 2, HJC0197 ([@B5]), and ESI-09 ([@B1]) (10 *μ*M, 20 minutes) did not prevent the inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ ([Fig. 2E](#F2){ref-type="fig"}). Higher concentrations (50 *μ*M) of either antagonist abolished the Ca^2+^ signals evoked by histamine (data not shown). We have not explored this effect further, although the antagonists caused similar inhibition of carbachol-evoked Ca^2+^ signals in human embryonic kidney 293 cells ([@B20]). Others have also reported nonspecific effects of these EPAC antagonists ([@B30]).

Maximally effective concentrations of PGE~2~, forskolin, NKH 477, or 8-Br-cAMP similarly attenuated the Ca^2+^ signals evoked by histamine, and combinations of the treatments were not additive ([Fig. 2D](#F2){ref-type="fig"}). These results establish that inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ is mediated by cAMP ([Fig. 2F](#F2){ref-type="fig"}) and does not require EPACs.

### Inhibition of Histamine-Evoked Ca^2+^ Signals by PGE~2~ is Not Mediated by cGMP-Dependent Protein Kinase. {#s17}

Cyclic AMP may directly activate PKG in arterial smooth muscle, although this is contentious \[see references in [@B24]\]. Cyclic AMP could, however, increase the concentration of cGMP by competing with it for degradation by cyclic nucleotide phosphodiesterases (PDEs). Stimulation of PKG might then attenuate IP~3~-evoked Ca^2+^ release ([@B19]). There is evidence, however, that expression of proteins involved in PKG signaling in VSM are downregulated in culture ([@B17], and references therein). 8-Br-cGMP (pIC~50~ = 4.50 ± 0.29, *n* = 5) partially inhibited Ca^2+^ signals evoked by a submaximal concentration of histamine, but the maximal inhibition was less than half that evoked by PGE~2~ or 8-Br-cAMP ([Fig. 3, A and B](#F3){ref-type="fig"}). Furthermore, and in contrast to the effects of 8-Br-cAMP ([Fig. 2C](#F2){ref-type="fig"}), 8-Br-cGMP did not inhibit the Ca^2+^ signals evoked by a maximal histamine concentration ([Fig. 2D](#F2){ref-type="fig"}). Prolonged incubation with IBMX (20 minutes, 1 mM), a nonselective inhibitor of PDEs, inhibited histamine-evoked Ca^2+^ signals, but the inhibition (33% ± 3%, *n* = 4) was less than that caused by PGE~2~ (56% ± 3%) ([Fig. 3C](#F3){ref-type="fig"}). More importantly, a maximal concentration of PGE~2~ similarly inhibited histamine-evoked Ca^2+^ signals in the presence and absence of IBMX ([Fig. 3C](#F3){ref-type="fig"}), demonstrating that the effects of PGE~2~ are not mediated by inhibition of PDEs. We conclude that inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ is not mediated by inhibition of PDEs and consequent accumulation of cGMP.

![Inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ is not mediated by cGMP. (A) Concentration-dependent effects of 8-Br-cGMP (20 minutes) on the peak Ca^2+^ signals evoked by histamine (3 *μ*M). (B) Similar experiments show the responses to histamine (3 *μ*M) after preincubation with PGE~2~ (10 *μ*M, 5 minutes) and/or the indicated concentrations of 8-Br-cAMP or 8-Br-cGMP (20 minutes). (C) Peak Ca^2+^ signals evoked by histamine alone or after incubation with IBMX (1 mM, 20 minutes), PGE~2~ (10 *μ*M, 5 minutes), or both. Results (as percentages of response to histamine alone) are means ± S.E.M. from five (A), three to six (B; *n* = 2 for 3 and 5 mM 8-Br-cAMP, where ranges are shown), and four to seven (C) independent experiments with two to three wells in each.](mol.117.109249f3){#F3}

### Histamine and 8-Br-cAMP Stimulate PKA-Mediated Protein Phosphorylation in Different Microenvironments. {#s18}

Most effects of cAMP are mediated by PKA, EPACs, or cyclic nucleotide-regulated plasma membrane cation channels ([@B10]; [@B6]). The latter cannot mediate the effects of cAMP on IP~3~-evoked Ca^2+^ release, nor are EPACs responsible. We therefore assessed the role of PKA.

Immunoblotting with an antiserum that recognizes sequences phosphorylated by PKA showed that maximally effective concentrations of PGE~2~ or 8-Br-cAMP stimulated similar levels of protein phosphorylation in ASMC and their effects were nonadditive ([Fig. 4A](#F4){ref-type="fig"}). The phosphorylation was mimicked by 6-Bnz-cAMP but not by the EPAC-selective analog 8-pCPT-2*′*-O-Me-cAMP ([Fig. 4A](#F4){ref-type="fig"}). PGE~2~-evoked protein phosphorylation was attenuated by inhibition of either PKA (with H89) or AC \[with 1 mM SQ 22536 with 200 *μ*M DDA (SQ/DDA)\] ([Fig. 4B](#F4){ref-type="fig"}).

![PGE~2~ and 8-Br-cAMP stimulate PKA-mediated protein phosphorylation. (A) Typical immunoblot using AbP2 (see *Materials and* *Methods*) showing PKA-phosphorylated proteins from cells stimulated with cAMP analogs (10 mM, 20 minutes) or PGE~2~ (10 *μ*M, 5 minutes). Summary results (means ± S.D., *n* = 3--4) show the band intensity across the entire gel as a percentage of that from cells stimulated with PGE~2~. M~r~ markers (kilodaltons) shown alongside gel. (B) Similar analyses using AbP1 show the effects of H89 (10 *μ*M, 10 minutes) or SQ/DDA (1 mM SQ22536 and 200 *μ*M DDA, 20 minutes) on the phosphorylation of a 75-kDa band in response to PGE~2~ (10 *μ*M. 5 minutes). Summary results (means ± S.D., *n* = 3--5) show band intensities as percentages of the matched response to PGE~2~ alone. (C) Similar analysis to (A), for cells stimulated with PGE~2~ (10 *μ*M, 5 minutes) or 8-Br-cAMP (10 mM, 20 minutes) alone or after incubation (20 minutes) with *R*p-8-CPT-cAMPS (1 mM) H89 (10 *μ*M). Results (means ± S.D., *n* = 3--4) show the increase in phosphorylation evoked by the indicated stimuli expressed as a percentage of the matched response to PGE~2~ alone.](mol.117.109249f4){#F4}

Maximal concentrations of PGE~2~ and 8-Br-cAMP caused phosphorylation of the same proteins ([Fig. 4A](#F4){ref-type="fig"}), but the two stimuli differed in their susceptibility to PKA inhibitors. *R*p-8-CPT-cAMPS, an inhibitor of PKA that competes with cAMP by binding to the regulatory subunit of PKA, abolished the phosphorylation evoked by 8-Br-cAMP but only partially inhibited that evoked by PGE~2~ ([Fig. 4C](#F4){ref-type="fig"}). Conversely, H89, which inhibits PKA (and other kinases) by competing for the ATP-binding site, abolished the phosphorylation evoked by PGE~2~ but caused lesser inhibition of the response to 8-Br-cAMP ([Fig. 4C](#F4){ref-type="fig"}). Similar results were obtained when an antiserum to phospho-VASP was used to assess PKA-mediated phosphorylation ([Supplemental Fig. S2](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.117.109249/-/DC1)).

These results suggest that PKA activated by PGE~2~ may be exposed to high local concentrations of cAMP, which might then effectively compete with the inhibitor *R*p-8-CPT-cAMPS. Conversely, PKA activated by 8-Br-cAMP, which would probably be uniformly distributed within the cell, may be more accessible to ATP than PKA activated by PGE~2~, and so less susceptible to inhibition by H89.

### Inhibition of Histamine-Evoked Ca^2+^ Signals by PGE~2~ Is Attenuated by Inhibition of PKA. {#s19}

Inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ or 8-Br-cAMP was inhibited by *R*p-8-CPT-cAMPS (1 mM), which reduced the sensitivity to PGE~2~ (decreasing the pIC~50~ for PGE~2~ from 8.68 ± 0.17 to 8.26 ± 0.05, *n* = 3; *Δ*pIC~50~ = 0.4 ± 0.1, where *Δ*pIC~50~ = pIC~50~^control^ -- pIC~50~*^R^*^p-8-CPT-cAMPS^) and 8-Br-cAMP (*Δ*pIC~50~ = 0.6 ± 0.1) without affecting the maximal inhibition ([Fig. 5, A and B](#F5){ref-type="fig"}). These results are consistent with *R*p-8-CPT-cAMPS competitively inhibiting cAMP binding to PKA and thereby attenuating the effects of cAMP on Ca^2+^ signals.

![Inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ or 8-Br-cAMP requires PKA. (A and B) Effects of PGE~2~ (5 minutes) or 8-Br-cAMP (20 minutes) on the peak Ca^2+^ signals evoked by histamine (3 *μ*M) alone or with H89 (10 *μ*M, 20 minutes) or *R*p-8-CPT-cAMPS (1 mM, 20 minutes). (C) Effects of PGE~2~ (5 minutes) on the Ca^2+^ signals evoked by histamine (3 *μ*M) in cells infected with baculovirus expressing PKI or its inactive form (mut PKI). Results (A--C) are means ± S.E.M. from three experiments with two to three wells in each. (D) The results suggest that PKA mediates the inhibition of histamine-evoked Ca^2+^ signals by PGE~2~.](mol.117.109249f5){#F5}

H89 (10 *μ*M) also attenuated the inhibition of histamine-evoked Ca^2+^ signals by 8-Br-cAMP (*Δ*pIC~50~ = 1.13 ± 0.18 *n* = 3) and PGE~2~ ([Fig. 5, A and B](#F5){ref-type="fig"}). In keeping with our analyses of protein phosphorylation ([Fig. 4C](#F4){ref-type="fig"}), the inhibition of histamine-evoked Ca^2+^ signals by maximal concentrations of PGE~2~ were less effectively inhibited by H89 than were the effects of maximal concentrations of 8-Br-cAMP (compare [Fig. 5, A and B](#F5){ref-type="fig"}).

PKI inhibits PKA by competing with its peptide substrates. We could not achieve effective inhibition of PKA-mediated protein phosphorylation with myristoylated-PKI (10 *μ*M, 20 minutes, data not shown). But using a baculovirus, we achieved expression of PKI in \>90% of cells, and this caused 49% ± 6% (*n* = 3) inhibition of the VASP phosphorylation evoked by PGE~2~ (100 nM) ([Supplemental Fig. S3](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.117.109249/-/DC1)). Expression of an inactive PKI (mut PKI) had no effect on PGE~2~-evoked protein phosphorylation ([Supplemental Fig. S3](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.117.109249/-/DC1)). The effects of H89 and PKI on the inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ were similar: Each substantially reduced the maximal inhibition without significantly affecting the IC~50~ for PGE~2~ ([Fig. 5, A and C](#F5){ref-type="fig"}). The effects of H89 on inhibition of histamine-evoked Ca^2+^ signals by selective agonists of EP~2~ (butaprost) and EP~4~ (L902,688) receptors were similar to those observed with PGE~2~ ([Supplemental Fig. S4](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.117.109249/-/DC1)). We conclude that inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ is mediated by cAMP and requires PKA ([Fig. 5D](#F5){ref-type="fig"}).

### PGE~2~ Does Not Inhibit Ca^2+^ Release Evoked by Direct Activation of IP~3~Rs. {#s20}

The rate at which \[Ca^2+^\]~i~ recovered from the peak Ca^2+^ signal evoked by histamine was unaffected by PGE~2~ (half-times for recovery were 19 ± 1 and 17 ± 1 seconds, after histamine alone or with PGE~2~, respectively; *n* = 11) ([Supplemental Fig. S5](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.117.109249/-/DC1)). This suggests that the attenuated Ca^2+^ signals do not result from PGE~2~ stimulating Ca^2+^ extrusion from the cytosol.

We used flash-photolysis of ci-IP~3~ to activate IP~3~R directly in Fluo-4-loaded ASMC. Single-cell analyses of ASMC established that most cells (99% ± 1%, from 12 fields) responded to histamine (1 mM) with an increase in \[Ca^2+^\]~i~, and that two successive challenges with histamine evoked indistinguishable Ca^2+^ signals ([Fig. 6, A and B](#F6){ref-type="fig"}). PGE~2~ reduced the peak amplitude of the Ca^2+^ signal evoked by a second histamine challenge by 28% ± 4% (*n* = 65 cells), without significantly affecting the number of cells that responded (91% ± 8% and 83% ± 7% for control and PGE~2~-treated cells, respectively) ([Fig. 6, C and D](#F6){ref-type="fig"}). These results confirm that under the conditions used for uncaging ci-IP~3~, PGE~2~ inhibits histamine-evoked Ca^2+^ signals.

![PGE~2~ does not inhibit Ca^2+^ signals evoked by direct activation of IP~3~ receptors. (A--D) Typical fluorescence traces from single Fura-2-loaded ASMC sequentially stimulated with histamine (1 mM) alone (A) or with PGE~2~ (10 *μ*M) (C). Summary results (means ± S.E.M., 65 cells from six independent fields) show peak amplitudes of the first and second responses to histamine in the absence (B) or presence (D) of PGE~2~. (E) Typical fluorescence traces from single Fluo-4-loaded ASMC stimulated with a UV flash to photolyse ci-IP~3~ (red trace) or histamine (1 mM, black trace). (F) Summary results (means ± S.E.M. from 35 and 118 cells, for histamine and ci-IP~3~ respectively) show peak responses. (G and H) Three typical fluorescence traces from single ASMC stimulated twice with UV flashes (arrowheads) alone (G) or with PGE~2~ (10 *μ*M) (H). (I) Summary results (means ± S.E.M. from 50--68 cells) show relative amplitudes of the peak responses (R2/R1). (J) Summary results (means ± S.E.M. from 36--43 cells) show F/F~0~ (see *Materials and* *Methods*) for cells stimulated with a UV flash alone or with PGE~2~ (10 *μ*M added 5 minutes before flash). \**P* \< 0.05, relative to the response to histamine alone (D, paired Student's *t* test) or to the UV flash alone (F, unpaired Student's *t* test).](mol.117.109249f6){#F6}

ASMC loaded with ci-IP~3~ responded to UV flashes with rapid increases in Fluo-4 fluorescence (F/F~0~, see *Materials and* *Methods*). The amplitudes of these signals were less than those evoked by a maximal concentration of histamine ([Fig. 6, E and F](#F6){ref-type="fig"}), confirming that responses to photolysis of ci-IP~3~ were not saturated. Although cells responded similarly to successive histamine challenges ([Fig. 6, A and B](#F6){ref-type="fig"}), the response to a second photolysis of ci-IP~3~ was smaller than the first ([Fig. 6G](#F6){ref-type="fig"}), presumably because each stimulus depleted a fraction of the ci-IP~3~. We therefore used two methods to assess the effects of PGE~2~ on the Ca^2+^ signals evoked by photolysis of ci-IP~3~. Cells were either stimulated twice with a UV stimulus, and the amplitude of the second response (with or without PGE~2~) was compared with the first response for each cell (R2/R1) ([Fig. 6, G--I](#F6){ref-type="fig"}), or cells were stimulated once with UV flashes alone or in the presence of PGE~2~ ([Fig. 6J](#F6){ref-type="fig"}). Both analyses concur in demonstrating that PGE~2~ has no significant effect on the Ca^2+^ signals evoked by IP~3~ ([Fig. 6, G--J](#F6){ref-type="fig"}). The results with ci-IP~3~ therefore demonstrate that PGE~2~ does not affect the interactions of IP~3~ with IP~3~R. Furthermore, because the peak IP~3~-evoked Ca^2+^ signals were unaffected by PGE~2~ under conditions where it attenuates responses to histamine ([Fig. 6, I and J](#F6){ref-type="fig"}), the results provide additional evidence that PGE~2~ does not stimulate Ca^2+^ removal from the cytosol.

The product of ci-IP~3~ photolysis is an active but modified form of IP~3~ ([d]{.smallcaps}-2,3-*O*-isopropylidene-*myo*-inositol 1,4,5-trisphosphate) ([@B7]) that is not a substrate for IP~3~ 3-kinase and may differ from IP~3~ in its rate of dephosphorylation. Our results do not therefore exclude the possibility that PGE~2~ may accelerate degradation of IP~3~. These results suggest that PGE~2~ attenuates histamine-evoked Ca^2+^ signals by inhibiting IP~3~ formation, stimulating IP~3~ degradation, and/or disrupting IP~3~ delivery to IP~3~Rs.

### PGE~2~ Attenuates Histamine-Evoked Accumulation of IP~3~. {#s21}

Using an assay that reports PLC activity (stimulation after blocking inositol monophosphate degradation by Li^+^), histamine (1 mM, 30 minutes) stimulated a small accumulation of ^3^H-inositol phosphates in ASMC. Although the response was modestly attenuated by PGE~2~ (10 *μ*M), the effect was not statistically significant ([Fig. 7A](#F7){ref-type="fig"}). Using an IP~3~R-based bioassay that detects only (1,4,5)IP~3~, histamine stimulated IP~3~ accumulation, and the response was attenuated by PGE~2~, although the latter again failed to achieve statistical significance ([Fig. 7B](#F7){ref-type="fig"}). We also attempted to measure histamine-evoked IP~3~ formation in single cells using a fluorescence resonance energy transfer (FRET)-based IP~3~ sensor ([@B12]), but the signals were too small to resolve reliably any inhibitory effect of PGE~2~. Available genetically encoded IP~3~ sensors are known to have limited dynamic range and limited capacity to resolve small changes in intracellular IP~3~ concentration ([@B21]).

![PGE~2~ selectively attenuates activation of PLC by histamine. (A) Accumulation of ^3^H-inositol phosphates (30 minutes) in cells incubated with LiCl and stimulated with histamine (1 mM) alone or with PGE~2~ (10 *μ*M). Results are shown as percentages of matched analyses from unstimulated cells. (B) Mass assays of (1,4,5)IP~3~ from cells treated with histamine (1 minute) alone or after treatment with PGE~2~ (10 *μ*M, 5 minutes). Results (A and B) are means ± S.E.M., *n* = 3--5, \**P* \< 0.05, relative to 1 mM histamine, one-way analysis of variance with Bonferroni's test. (C) Peak Ca^2+^ signals evoked by the indicated concentrations of thrombin or PAR1 peptide. (D) Effects of PGE~2~ (10 *μ*M, 5 minutes) on the peak Ca^2+^ signals evoked by the indicated concentrations of histamine or PAR1 peptide. Results (C and D) are means ± S.E.M., *n* = 4--5. (E) Comparison of the effects of PGE~2~ on Ca^2+^ signals of similar amplitude evoked by histamine or PAR1 peptide. (F) Peak increases in \[Ca^2+^\]~i~ in ASMC heterologously expressing M3 muscarinic receptors and stimulated in Ca^2+^-free HBS with the indicated concentrations of carbachol alone or with PGE~2~ (10 *μ*M, 5 minutes). Results are means ± S.E.M., *n* = 3, with six replicates for each. There was no response to carbachol in normal ASMC (data not shown).](mol.117.109249f7){#F7}

We assessed the responses of ASMC to other stimuli (ATP, bradykinin, carbachol, phenylephrine, and thrombin) that might be expected to evoked Ca^2+^ signals through receptors that stimulate Gq (results not shown). Only thrombin reproducibly evoked substantial increases in \[Ca^2+^\]~i~. Thrombin is a protease that cleaves the type 1 protease-activated receptor (PAR1) to unmask an N-terminal ligand. Thrombin and the PAR1 peptide itself evoked concentration-dependent increases in \[Ca^2+^\]~i~ in ASMC ([Fig. 7C](#F7){ref-type="fig"}). In parallel analyses, PGE~2~ (10 *μ*M, 5 minutes) attenuated the Ca^2+^ signals evoked by histamine without affecting those evoked by PAR1 peptide ([Fig. 7D](#F7){ref-type="fig"}). Although the maximal increase in \[Ca^2+^\]~i~ evoked by PAR1 peptide was larger than that evoked by histamine, with concentrations of histamine and the PAR1 peptide that evoked comparable increases in \[Ca^2+^\]~i~, only the response to histamine was inhibited by PGE~2~ ([Fig. 7E](#F7){ref-type="fig"}). After heterologous expression of human muscarinic M3 acetylcholine receptors in ASMC, carbachol evoked a concentration-dependent (pEC~50~ = 7.72 ± 0.04, *n* = 3) increase in \[Ca^2+^\]~i~, with a maximal increase (272 ± 31 nM, *n* = 3) comparable to that evoked by histamine (204 ± 13 nM, [Fig. 2A](#F2){ref-type="fig"}). However, the responses to carbachol were unaffected by PGE~2~ ([Fig. 7F](#F7){ref-type="fig"}). These results, demonstrating that PGE~2~ selectively inhibits the Ca^2+^ signals evoked by histamine, suggest that the inhibition probably does not arise downstream of PLC.

### Histamine-Evoked Ca^2+^ Signals Are Inhibited by Local cAMP Signals. {#s22}

Inhibitors of AC (SQ/DDA) attenuated PGE~2~-evoked cAMP formation (by 79% ± 2%, *n* = 4) ([Fig. 8A](#F8){ref-type="fig"}) and protein phosphorylation ([Fig. 4B](#F4){ref-type="fig"}). However, SQ/DDA had no effect on the inhibition of histamine-evoked Ca^2+^ signals evoked by PGE~2~ or butaprost ([Fig. 8, B and C](#F8){ref-type="fig"}). Although cAMP mediates the inhibition of Ca^2+^ signals by PGE~2~, the response to a maximal concentration of PGE~2~ might survive substantial inhibition of AC because it stimulates formation of more cAMP than needed to maximally inhibit Ca^2+^ signals ([Fig. 1B](#F1){ref-type="fig"}). However, the same argument cannot account for the lack of effect of SQ/DDA on responses to submaximal concentrations of PGE~2~. How might a submaximal response to PGE~2~ be unaffected by substantial inhibition of cAMP formation and PKA activity ([Fig. 4B](#F4){ref-type="fig"}; [Fig. 8, A and B](#F8){ref-type="fig"})?

![Signaling from EP receptors to Ca^2+^ signals via cAMP junctions. (A) Concentration-dependent effects of PGE~2~ on intracellular cAMP (5 minutes) alone or after treatment with SQ/DDA (20 minutes). Results \[cAMP/(ATP + ADP + cAMP), %\] are means ± S.E.M. from four experiments \[three of these were published in [@B28]\]. (B--D) Concentration-dependent effects of PGE~2~, butaprost, or L902,688 on the Ca^2+^ signals evoked by histamine (3 *μ*M) in the presence of SQ/DDA (20 minutes). Results are means ± S.E.M. from nine (B), six (C), or five (D) experiments with two to three wells in each. (E) Summary data show the effects of SQ/DDA on the inhibition of histamine-evoked Ca^2+^ signals by concentrations of PGE~2~ (1 nM), butaprost (30 nM), and L902,688 (0.3 nM) that approximately match their IC~50~ values. (F) Junctional delivery of cAMP to the PKA (squares) through which it inhibits (red) histamine-evoked Ca^2+^ signals. Activation of EP~2~ or EP~4~ receptors with butaprost or L902,688, respectively, inhibits histamine-evoked Ca^2+^ signals, but the latter evokes formation of less cAMP. We propose, from our results with SQ/DDA, that cAMP is locally delivered to PKA within each signaling junction at a concentration more than sufficient to cause a maximal effect. The concentration-dependent inhibition of Ca^2+^ signals by prostanoids is proposed to result from recruitment of all-or-nothing cAMP signaling junctions, rather than from graded increases in activity within individual junctions. EP~2~ receptors deliver more cAMP than EP~4~ receptors and are therefore more resistant to inhibition of AC by SQ/DDA. Hence inhibition of Ca^2+^ signals by EP~4~ receptors is partially inhibited by SQ/DDA, whereas the response to EP~2~ receptors is insensitive (right). \**P* \< 0.05, paired Student\'s *t*-test relative to control.](mol.117.109249f8){#F8}

A possible explanation is that SQ 22356 and DDA, related inhibitors that bind to the ATP-binding site of AC ([@B4]), selectively inhibit subtypes of AC distinct from those that mediate the effects of PGE~2~. Available antibodies do not allow quantitative assessment of the expression of AC subtypes, but QPCR analysis shows that human ASMC express similar amounts (∼30%) of AC3, AC7, AC9, some AC6 (∼10%), and detectable AC4 (∼2%) ([Supplemental Fig. S6](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.117.109249/-/DC1)). AC9 probably does not mediate the effects of PGE~2~ on Ca^2+^ signals because AC9 is insensitive to forskolin and NKH 477 ([@B34]), which mimic the effects of PGE~2~ on Ca^2+^ signals ([Fig. 1, C--E](#F1){ref-type="fig"}; [Fig. 2D](#F2){ref-type="fig"}). Among the remaining ACs expressed in ASMC, SQ22536 and DDA probably have some selectivity for AC6 over AC3 and AC7 despite some inconsistent reports ([@B29]; [@B34]). From analyses of individual AC isoforms, maximally effective concentrations of SQ 22356 (and other P-site inhibitors) inhibit catalytic activity by only ∼80% \[[@B4], but see [@B27]\]. This is similar to the ∼80% inhibition of PGE~2~-evoked cAMP accumulation by SQ/DDA in ASMC ([Fig. 8A](#F8){ref-type="fig"}), suggesting that the incomplete inhibition observed in ASMC probably does not reflect the unperturbed activity of SQ/DDA-insensitive ACs. Furthermore, the effects of PGE~2~ on protein phosphorylation in ASMC are inhibited by SQ/DDA ([Fig. 4B](#F4){ref-type="fig"}), again suggesting that the ACs activated by PGE~2~ are inhibited. We conclude that the lack of effect of SQ/DDA on PGE~2~-mediated inhibition of histamine-evoked Ca^2+^ signals is probably not the result of ineffective inhibition of an SQ/DDA-resistant subtype of AC.

To account for the results with SQ/DDA, we suggest that cAMP is delivered locally to PKA at concentrations more than sufficient to fully inhibit Ca^2+^ signals. The concentration-dependent effects of PGE~2~ might then result from recruitment of these "hyperactive" cAMP signaling junctions, rather than from increased activity within individual junctions ([Fig. 8F](#F8){ref-type="fig"}). This interpretation is consistent with analyses of the effects of SQ/DDA on the inhibition of Ca^2+^ signals by selective activation of EP~4~ receptors. Although activation of EP~2~ and EP~4~ receptors causes similar maximal inhibition of histamine-evoked Ca^2+^ signals, EP~4~ receptors cause less stimulation of AC ([@B28]). This suggests that EP~4~ receptors may less effectively saturate the cAMP signaling junctions. Whereas inhibition of AC with SQ/DDA had no effect on the inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ or butaprost (to selectively activate EP~2~ receptors), the sensitivity to L902,688, a selective agonist of EP~4~ receptors, was modestly reduced by SQ/DDA (*Δ*pIC~50~ = 0.32 ± 0.10, *n* = 5) ([Fig. 8, B--E](#F8){ref-type="fig"}). This observation supports our suggestion that the subtype(s) of AC that link prostanoid receptors to inhibition of Ca^2+^ signals are sensitive to SQ/DDA. Furthermore, these results are consistent with the scheme shown in [Fig. 8F](#F8){ref-type="fig"}, where we suggest that cAMP is locally delivered within "hyperactive" signaling junctions at concentrations more than sufficient to maximally activate the PKA that inhibits Ca^2+^ signals.

We considered whether AKAPs, which are widely implicated in assembling PKA with its regulators and effectors ([@B35]), might contribute to organization of the cAMP signaling through PKA that leads to inhibition of histamine-evoked Ca^2+^ signals. A membrane-permeant peptide that disrupts association of AKAPs with PKA (st-Ht31) but not its inactive analog (st-Ht31P), significantly attenuated the protein phosphorylation evoked by PGE~2~, but neither peptide affected the concentration-dependent inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ ([Supplemental Fig. S7](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.117.109249/-/DC1)). These results suggest that AKAPs are probably not important components of the signaling pathway from PGE~2~ to inhibition of Ca^2+^ signals.

Discussion {#s23}
==========

In human ASMC, the IP~3~-mediated Ca^2+^ signals evoked by activation of H~1~ histamine receptors are attenuated by PGE~2~. Several lines of evidence show that this inhibition is mediated by cAMP. The concentration-effect relationships for regulation of AC and Ca^2+^ signals by PGE~2~ are consistent with cAMP lying upstream of Ca^2+^ in the signaling pathway ([Fig. 1B](#F1){ref-type="fig"}), direct activation of AC or membrane-permeant analogs of cAMP mimic PGE~2~, and maximal concentrations of these drugs are not additive ([Figs. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). Our conclusion that cAMP mediates the inhibition of Ca^2+^ signals in human ASMC is consistent with evidence that many receptors, via stimulation of AC, attenuate Ca^2+^ signaling in smooth muscle, including VSM ([@B23]). Inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ does not require activation of EPACs ([Fig. 2, D and E](#F2){ref-type="fig"}). The inhibition is not mediated by accumulation of cGMP after inhibition of PDEs since neither cGMP nor inhibition of PDEs effectively mimicked PGE~2~ ([Fig. 3](#F3){ref-type="fig"}). Inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ or 8-Br-cAMP was attenuated by inhibition of PKA using H89, PKI, or *R*p-8-CPT-cAMPS ([Fig. 4](#F4){ref-type="fig"}). We conclude that inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ is (at least largely) mediated by PKA ([Fig. 5D](#F5){ref-type="fig"}).

PKA can enhance Ca^2+^ removal from the cytosol by stimulating Ca^2+^ pumps ([@B38]) or the Na^+^/Ca^2+^ exchanger ([@B15]). However, accelerated removal of cytosolic Ca^2+^ does not mediate inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ in human ASMC ([Supplemental Fig. S5](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.117.109249/-/DC1)). Nor would this mechanism be consistent with the lack of effect of PGE~2~ on the Ca^2+^ signals evoked by stimulation of endogenous PAR1 or heterologously expressed M3 muscarinic receptors ([Fig. 7, D--F](#F7){ref-type="fig"}). Cyclic AMP has been proposed to inhibit IP~3~-evoked Ca^2+^ release ([@B2]), but PKA (IP~3~R1 and IP~3~R2) and cAMP (IP~3~R1-3) more often potentiate responses to IP~3~ ([@B39]). However, under conditions where PGE~2~ inhibited histamine-evoked Ca^2+^ signals, it had no effect on the sensitivity of IP~3~Rs to IP~3~ ([Fig. 6](#F6){ref-type="fig"}). Steps linking receptors to PLC can also be inhibited by cAMP (see references in [@B43]). Although two different assays suggested that PGE~2~ attenuated histamine-evoked PLC activity in human ASMC, neither analysis demonstrated a statistically significant effect ([Fig. 7, A and B](#F7){ref-type="fig"}). However, the lack of effect of PGE~2~ on the Ca^2+^ signals evoked by PAR1 and muscarinic M3 receptors ([Fig. 7, D--F](#F7){ref-type="fig"}) suggests that the inhibition of histamine-evoked Ca^2+^ signals by cAMP/PKA is probably the result of uncoupling of H~1~ histamine receptors from G~q/11~. PKA has been reported to phosphorylate H~1~ histamine receptors ([@B16]; [@B13]), but the functional consequences have not been thoroughly examined ([@B22]). We conclude that in human ASMC, PGE~2~, through EP~2~ and EP~4~ receptors ([@B28]), stimulates AC, leading to formation of cAMP and uncoupling of histamine from stimulation of PLC, most probably by PKA-mediated phosphorylation of H~1~ receptors.

Cyclic AMP can be locally delivered to intracellular targets ([@B45]; [@B6]). AKAPs play prominent roles in targeting cAMP through PKA to specific cellular responses ([@B35]), but our results suggest that AKAPs probably do not contribute to inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ ([Supplemental Fig. S7](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.117.109249/-/DC1)). Our results do, however, reveal an additional complexity in the pathways linking PGE~2~ to inhibition of histamine-evoked Ca^2+^ signals. Although cAMP mediates this inhibition, the concentration-dependent effects of PGE~2~ were insensitive to substantial inhibition of AC ([Fig. 8](#F8){ref-type="fig"}). These results and analyses of the effects of selective activation of EP~2~ and EP~4~ receptors lead to the scheme shown in [Fig. 8F](#F8){ref-type="fig"}. We suggest that communication between EP receptors and the PKA that inhibits histamine-evoked IP~3~ formation is mediated by delivery of cAMP within signaling junctions. Activation of a junction allows local delivery of a supersaturating concentration of cAMP to PKA, allowing each junction to function as a robust on-off switch. We suggest that the concentration-dependent effects of PGE~2~ arise from recruitment of these junctions and not from graded activity within individual junctions. Such digital signaling from receptors to intracellular targets via hyperactive junctions ([Fig. 8F](#F8){ref-type="fig"}) allows robust and reliable communication, and may be a general feature of signaling by diffusible intracellular messengers ([@B41]).
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AC

:   adenylyl cyclase

AKAP

:   A kinase-anchoring protein

ASMC

:   aortic smooth muscle cell

\[Ca^2+^\]~i~

:   intracellular free \[Ca^2+^\]

ci-IP~3~

:   [d]{.smallcaps}-2,3-*O*-isopropylidene-6-*O*-(2-nitro-4,5-dimethoxy)benzyl-*myo*-inositol 1,4,5-trisphosphate; ci-IP~3~PM, ci-IP3-hexakis(propionoxymethyl) ester

DDA

:   2*′*,5*′*-dideoxyadenosine

EPAC

:   exchange protein activated by cAMP

ESI-09

:   3-\[5-(*tert*-butyl)isoxazol-3-yl\]-2-\[2-(3-chlorophenyl)hydrazono\]-3-oxopropanenitrile

HBS

:   HEPES-buffered saline

HJC0197

:   4-cyclopentyl-2-(2,5-dimethylbenzylsulfanyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile

H89

:   *N*-\[2-\[\[3-(4-bromophenyl)-2-propenyl\]amino\]ethyl\]-5-isoquinolinesulfonamide dihydrochloride

IBMX

:   3-isobutyl-1-methylxanthine

IP~3~

:   inositol 1,4,5-trisphosphate

IP~3~R

:   IP~3~ receptor

L902

:   688 (5-\[(1*E*,3*R*)-4,4-difluoro-3-hydroxy-4-phenyl-1-buten-1-yl\]-1-\[6-(2*H*-tetrazol-5*R*-yl)hexyl\]-2-pyrrolidinone)

NKH 477

:   (*N*,*N*-dimethyl-(3*R*,4a*R*,5*S*,6a*S*,10*S*,10a*R*,10b*S*)-5-(acetyloxy)-3-ethenyldodecahydro-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-1*H*-naphtho\[2,1-*b*\]pyran-6-yl ester *β*-alanine hydrochloride)

PAR1

:   protease-activated receptor type 1

PDE

:   cyclic nucleotide phosphodiesterase

pIC~50~ (pEC~50~)

:   negative logarithm of the half-maximally inhibitory (effective) concentration

PGE~2~

:   prostaglandin E~2~

PKA

:   cAMP-dependent protein kinase

PKG

:   cGMP-dependent protein kinase

PKI (mut PKI)

:   PKA inhibitor peptide (mutant inactive form)

PLC

:   phospholipase C

SQ 22536

:   9-(tetrahydro-2-furanyl)-9*H*-purin-6-amine

SQ/DDA

:   1 mM SQ 22536 with 200 *μ*M DDA

TBS

:   Tris-buffered saline

TBS-T

:   TBS with Tween

VASP

:   vasodilator-stimulated phosphoprotein

VSM

:   vascular smooth muscle
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